Published in Int J Tryptophan Res on June 10, 2010
M. tuberculosis induces potent activation of IDO-1, but this is not essential for the immunological control of infection. PLoS One (2012) 0.96
Oxidative stress and the HIV-infected brain proteome. J Neuroimmune Pharmacol (2013) 0.92
Tryptophan Catabolism in Chronic Viral Infections: Handling Uninvited Guests. Int J Tryptophan Res (2015) 0.83
Role of NAD(+), Oxidative Stress, and Tryptophan Metabolism in Autism Spectrum Disorders. Int J Tryptophan Res (2013) 0.83
Anti-retroviral therapy decreases but does not normalize indoleamine 2,3-dioxygenase activity in HIV-infected patients. PLoS One (2014) 0.83
The biochemical pathways of central nervous system neural degeneration in niacin deficiency. Neural Regen Res (2014) 0.81
Oxidative Stress during HIV Infection: Mechanisms and Consequences. Oxid Med Cell Longev (2016) 0.81
Influence of Hepatitis C Virus Sustained Virological Response on Immunosuppressive Tryptophan Catabolism in ART-Treated HIV/HCV Coinfected Patients. J Acquir Immune Defic Syndr (2016) 0.77
Kynurenic Acid Metabolism in Various Types of Brain Pathology in HIV-1 Infected Patients. Int J Tryptophan Res (2012) 0.76
Two new tryptophan derivatives from the seed kernels of Entada rheedei: effects on cell viability and HIV infectivity. Fitoterapia (2013) 0.75
Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals. Int J Tryptophan Res (2016) 0.75
Aspects of Tryptophan and Nicotinamide Adenine Dinucleotide in Immunity: A New Twist in an Old Tale. Int J Tryptophan Res (2017) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 10.08
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79
Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med (2006) 6.15
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 4.88
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol (2002) 3.80
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28
The spectrum of behaviors influenced by serotonin. Biol Psychiatry (1998) 2.98
Transcriptional abnormalities in Huntington disease. Trends Genet (2003) 2.91
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science (1990) 2.87
Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science (1983) 2.79
Neuronal loss in the frontal cortex in HIV infection. Lancet (1991) 2.71
Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov (2002) 2.61
The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci (2001) 2.61
Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry (1998) 2.55
Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol (2003) 2.54
Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol (1992) 2.52
Electron transport chain defects in Alzheimer's disease brain. Neurology (1994) 2.51
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature (1986) 2.29
Tryptophan and the immune response. Immunol Cell Biol (2003) 2.26
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene (2007) 2.24
MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem (2003) 2.21
Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol (1992) 2.21
Neocortical damage during HIV infection. Ann Neurol (1991) 2.15
AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol (1995) 2.14
Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem (2007) 2.12
Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem (1987) 2.09
Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain (1992) 2.09
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol (1991) 2.08
Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04
IDO and tolerance to tumors. Trends Mol Med (2004) 2.03
Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem (1991) 2.01
Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem (2004) 1.99
Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem (2004) 1.98
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia (2005) 1.93
beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem (2001) 1.92
Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology (2006) 1.88
A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem (1989) 1.82
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol (2005) 1.79
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem (2001) 1.79
Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta (1998) 1.71
Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol (2000) 1.69
Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am J Pathol (1990) 1.67
Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res (2007) 1.62
Evolution of HIV dementia with HIV infection. Int Rev Psychiatry (2008) 1.58
3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem (1998) 1.58
The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes. Proc Natl Acad Sci U S A (1993) 1.57
Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci (2007) 1.56
Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry (2005) 1.55
Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology (2007) 1.53
Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol (1995) 1.53
Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta (1999) 1.52
Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their projections in the guinea-pig small intestine. Neuroscience (1982) 1.52
Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand (2003) 1.51
The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci (2001) 1.51
Mitochondrial nitric oxide synthase. Trends Pharmacol Sci (2005) 1.50
Transport of tryptophan into brain from the circulating, albumin-bound pool in rats and in rabbits. J Neurochem (1990) 1.50
Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem (1999) 1.48
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2007) 1.48
Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem (1998) 1.46
The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology (2001) 1.46
Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol (1992) 1.45
Characterization of the kynurenine pathway in human neurons. J Neurosci (2007) 1.44
Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol (2007) 1.41
Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr (1990) 1.39
Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res (2004) 1.38
Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol (1988) 1.37
Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood (2004) 1.34
Organic ion transport during seven decades. The amino acids. Biochim Biophys Acta (1984) 1.32
The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol (2005) 1.32
Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem (2005) 1.31
Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol (2000) 1.30
Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett (1984) 1.29
Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience (1993) 1.27
Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med (2006) 1.25
Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest (1993) 1.25
Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol (2004) 1.24
Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience (1998) 1.24
Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol (2007) 1.23
Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol (1992) 1.22
L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res (1980) 1.21
Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol (2005) 1.21
Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J Immunol (2006) 1.19
Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines. Cytokine (1995) 1.19
Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem (1990) 1.19
Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res (1991) 1.17
Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol (2001) 1.17
Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol (1999) 1.16
Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res (2005) 1.16
The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One (2009) 1.15
Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem (2007) 1.15
Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. Neuroreport (1992) 1.15
Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol (1990) 1.14
Kynurenine pathway abnormalities in Parkinson's disease. Neurology (1992) 1.14
Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther (1997) 1.14
Neurological complications of HIV infection. Lancet Neurol (2005) 3.25
Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (2003) 2.69
Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol (2003) 2.50
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia (2005) 1.93
A protocol-driven model for the rapid initiation of stroke thrombolysis in the emergency department. Med J Aust (2007) 1.74
Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev (2009) 1.73
Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol (2008) 1.70
Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol (2004) 1.59
Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing (2005) 1.57
Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology (2006) 1.56
HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS (2010) 1.56
Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol (2011) 1.51
Characterization of the kynurenine pathway in human neurons. J Neurosci (2007) 1.44
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis (2012) 1.29
The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol (2005) 1.26
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol (2007) 1.22
Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J Interferon Cytokine Res (2007) 1.22
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res (2005) 1.16
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol (2013) 1.16
Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One (2011) 1.15
The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One (2009) 1.15
Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol (2003) 1.13
The neuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: a meta-analysis. J Int Neuropsychol Soc (2006) 1.11
HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. PLoS One (2013) 1.11
Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One (2011) 1.11
Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation (2005) 1.10
HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research. J Neurovirol (2014) 1.10
Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol (2011) 1.08
Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology (2012) 1.08
Participants' perspectives of high resolution anoscopy. Sex Health (2011) 1.08
Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One (2010) 1.08
Effects of Kynurenine Pathway Metabolites on Intracellular NAD Synthesis and Cell Death in Human Primary Astrocytes and Neurons. Int J Tryptophan Res (2009) 1.07
Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res (2009) 1.07
Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep (2002) 1.06
Participants' perspectives of self-collected anal cytological swabs. Sex Health (2011) 1.06
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol (2009) 1.06
Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J Neurochem (2008) 1.05
Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener Dis (2005) 1.04
The kynurenine pathway in brain tumor pathogenesis. Cancer Res (2012) 1.03
Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia (2003) 1.01
Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation (2009) 1.00
Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J Infect Dis (2004) 1.00
Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol (2003) 0.98
A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr (2012) 0.97
HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep (2014) 0.97
Facial emotional processing in HIV infection: relation to neurocognitive and neuropsychiatric status. Neuropsychology (2012) 0.97
Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease. Neurotox Res (2008) 0.93
Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS One (2013) 0.93
The burden of HIV-associated neurocognitive impairment in Australia and its estimates for the future. Sex Health (2011) 0.93
HIV and age do not substantially interact in HIV-associated neurocognitive impairment. J Neuropsychiatry Clin Neurosci (2011) 0.92
Validity of cognitive screens for HIV-associated neurocognitive disorder: a systematic review and an informed screen selection guide. Curr HIV/AIDS Rep (2013) 0.92
Global NeuroAIDS roundtable. J Neurovirol (2013) 0.92
Env gp120 sequence analysis of HIV type 1 strains from diverse areas of the brain shows preponderance of CCR5 usage. AIDS Res Hum Retroviruses (2006) 0.91
Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer (2004) 0.90
Possible JCV granular cell neuronopathy in a patient with HIV infection. Neurology (2009) 0.90
Statistical integration of 1H NMR and MRS data from different biofluids and tissues enhances recovery of biological information from individuals with HIV-1 infection. J Proteome Res (2011) 0.88
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox Res (2009) 0.88
First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia. Mol Neurodegener (2010) 0.88
Primary human astrocytes produce 24(S),25-epoxycholesterol with implications for brain cholesterol homeostasis. J Neurochem (2007) 0.88
Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex. Handb Clin Neurol (2007) 0.87
A report on the effect of commencing enfuvirtide on peripheral neuropathy. AIDS Res Hum Retroviruses (2008) 0.86
NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Res Ther (2013) 0.86
Evidence for predilection of macrophage infiltration patterns in the deeper midline and mesial temporal structures of the brain uniquely in patients with HIV-associated dementia. BMC Infect Dis (2009) 0.86
Lead dysregulates serine/threonine protein phosphatases in human neurons. Neurochem Res (2010) 0.86
A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport (2003) 0.86
Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int J Tryptophan Res (2010) 0.85
The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One (2013) 0.85
Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. J Neurovirol (2012) 0.85
NeuroAIDS in the Asia Pacific Region. J Neurovirol (2008) 0.84
The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. Neurotox Res (2007) 0.84
The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders. FEBS J (2012) 0.83
Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis. J Neurochem (2011) 0.82
The effects of HIV and aging on brain functions: proposing a research framework and update on last 3 years' findings. Curr Opin HIV AIDS (2014) 0.82
The kynurenine pathway in stem cell biology. Int J Tryptophan Res (2013) 0.81
The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication. Curr HIV/AIDS Rep (2015) 0.81
HIV, the brain, children, HAART and 'neuro-HAART': a complex mix. AIDS (2009) 0.80
Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS (2016) 0.80
Kynurenine Pathway Metabolism is Involved in the Maintenance of the Intracellular NAD Concentration in Human Primary Astrocytes. Int J Tryptophan Res (2010) 0.79
Quinolinic acid up-regulates chemokine production and chemokine receptor expression in astrocytes. Adv Exp Med Biol (2003) 0.79
Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study. BMC Neurol (2006) 0.79
Posterior reversible encephalopathy syndrome (PRES) in an HIV-1 infected patient with disseminated varicella zoster virus: a case report. BMC Infect Dis (2013) 0.78
Characterization of the kynurenine pathway and quinolinic Acid production in macaque macrophages. Int J Tryptophan Res (2013) 0.78
Benefit or toxicity from neurologically targeted antiretroviral therapy? Clin Infect Dis (2010) 0.78
Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. J Neurovirol (2013) 0.78
Alzheimer disease and HIV: a tangled story. Neurology (2010) 0.78
Neurological sequelae of primary HIV infection. Handb Clin Neurol (2007) 0.78
Strategies to target HIV-1 in the central nervous system. Curr Opin HIV AIDS (2016) 0.77
Serum nicotinamide adenine dinucleotide levels through disease course in multiple sclerosis. Brain Res (2013) 0.77